Male Breast Cancer Completed Phase 1 / 2 Trials for Denileukin diftitox (DB00004)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00425672ONTAKĀ® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous TreatmentTreatment